Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Wednesday, February 22 2017 12:13am ET - U.S. Markets open in 9 hours and 17 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > ESPERION THERAPEUTICS, INC. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
ESPERION THERAPEUTICS, INC. Company Profile
“Bad” cholesterol is public enemy #1 at Esperion Therapeutics. A biopharmaceutical company, Esperion researches and develops therapies that reduce elevated LDL-C levels in patients' blood. Its primary candidate, ETC-1002, has been under development since 2008 and is in clinical stage development. If the candidate is approved by the FDA, the company plans to market its drug to patients who are unable to physically tolerate widely used cholesterol drugs like statins. Esperion Therapeutics was formed in 2008 after former parent Pfizer spun the company's predecessor off. Esperion went public in 2013.
Headlines for ESPERION THERAPEUTICS, INC.
Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
GlobeNewswire - Wed Feb 15
Esperion Positioned to Capitalize on Phase III Trials
- Mon Feb 13
Harry Boxer’s stocks to watch: biotechnology and technology
at MarketWatch - Thu Feb 9
Four Biotech Stocks Breaking Out
at Forbes.com - Wed Feb 8
More Headlines...
More on ESPERION THERAPEUTICS, INC.
Quote Insider
News Financials
Profile    
Research    
Contact Information
Address: 3891 Ranchero Dr.,Ste. 150
Ann Arbor, MI 48108
Phone:734-887-3903
Fax:
Financial Highlights
Fiscal Year End:December
Revenue (2014):3.00 M
Employees (2014):21
Employee Growth (1 yr):23.50%
Key People
Executive Chairman, Chief Scientific Officer: Roger S. Newton
President, Chief Executive Officer and Director: Tim M. Mayleben
Chief Medical Officer: Noah L. Rosenberg
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
NOVARTIS PHARMACEUTICALS CORPORATION
Astrazeneca Pharmaceuticals LP
PFIZER INC. (pfe)
 


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?